Getting to Know Remdesivir, a US-Exported Drug to Overcome Corona

Healthy / 5 May, 2020

Getting to Know Remdesivir, a US-Exported Drug to Overcome Corona

Getting to Know Remdesivir, a US-Exported Drug to Overcome Corona
 which was released on May 12.

The FDA approved the emergency use of a drug made by Gilead Sciences, remdesivir for corona virus patients with severe symptoms.

The FDA defines severe as having low blood oxygen levels, requiring oxygen therapy, or using a ventilator.

The chief remdesivir maker, an anti-virus shown to reduce recovery time in COVID-19 patients, said on Sunday the company had exported the drug and made it available to patients in the United States through the US government.

Gilead Sciences CEO Daniel O’Day said the company donated the entire available drug supply – 1.5 million bottles, enough to treat 100,000 to 200,000 patients.

“We have been exporting for clinical trials and for using thousands of other treatments,” O’Day said on CBS “Face the Nation,” quoted by AFP.

Remdesivir vaccine is an antivirus developed by a biotechnology company based in the United States, Gilead Sciences. The vaccine with the development code GS-5734 belongs to the nucleotide analog class. This antivirus is synthesized in several ribose derivatives.

The US National Institute of Allergy and Infectious Disease (NIAID) says patients who use the drug have a faster recovery time than patients who only get a placebo.

The average recovery time for patients with remdesivir is 11 days. While patients who are only treated with placebo require recovery time of up to 15 days.

Remdesivir is an anti-vaccine, a nucleotide analog prodrug used for the treatment of Ebola and marburg virus infections in 2013-2016. This drug is also considered safe because it has been tested on people with Ebola before and does not cause adverse effects.

In a public statement posted on the official website of Gilead, this drug has shown in vitro and in vivo activity in animal models against MERS and SARS virus pathogens which are also part of the corona virus and are structurally similar to Covid-19. Remdesivir is an experimental drug that has no safety or efficacy for the treatment of any condition.

Gilead has begun two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 after a rapid test.